Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henning Schmidt

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Antimicrobial Agents and Chemotherapy|March 27, 2024
Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19Lindsay E Clegg, Oleg Stepanov, Henning Schmidt, et al.
Nature Communications|October 31, 2024
The replicative helicase CMG is required for the divergence of cell fates during asymmetric cell division in vivoNadin Memar, Ryan Sherrard, Aditya Sethi, et al.
Lung Cancer (Amsterdam, Netherlands)|September 10, 2015
Humoral immune responses of lung cancer patients against the Transmembrane Phosphatase with TEnsin homology (TPTE)Andreas Kuemmel, Petra Simon, Andrea Breitkreuz, et al.
European Journal of Haematology|July 12, 2018
<sup>90</sup> Y-ibritumomab-tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single-center experienceEva U Spukti, Lars Henning Schmidt, Arik Schulze, et al.
Oncoimmunology|July 30, 2013
HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patientsHans-Henning Schmidt, Yingzi Ge, Felix J Hartmann, et al.
Cancers|March 25, 2022
High Expression of NT5DC2 Is a Negative Prognostic Marker in Pulmonary AdenocarcinomaArik Bernard Schulze, Anna Kuntze, Lars Henning Schmidt, et al.
Plos Genetics|January 6, 2016
Prp4 Kinase Grants the License to Splice: Control of Weak Splice Sites during Spliceosome ActivationDaniela Eckert, Nicole Andrée, Aleh Razanau, et al.
Thoracic Cancer|November 25, 2019
Prognostic impact of CD34 and SMA in cancer-associated fibroblasts in stage I-III NSCLCArik Bernard Schulze, Lars Henning Schmidt, Birthe Heitkötter, et al.
Journal of Thoracic Disease|November 19, 2019
Blood clot removal by cryoextraction in critically ill patients with pulmonary hemorrhageLars Henning Schmidt, Arik Bernard Schulze, Dennis Goerlich, et al.
Translational Lung Cancer Research|May 17, 2023
High expression of transcription factor POU2F1 confers improved survival on smokers with lung adenocarcinoma: a retrospective study of two cohortsArik Bernard Schulze, Daniela Vanessa Wenge, Georg Evers, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Antimicrobial Agents and Chemotherapy|March 27, 2024
Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19Lindsay E Clegg, Oleg Stepanov, Henning Schmidt, et al.
Nature Communications|October 31, 2024
The replicative helicase CMG is required for the divergence of cell fates during asymmetric cell division in vivoNadin Memar, Ryan Sherrard, Aditya Sethi, et al.
Lung Cancer (Amsterdam, Netherlands)|September 10, 2015
Humoral immune responses of lung cancer patients against the Transmembrane Phosphatase with TEnsin homology (TPTE)Andreas Kuemmel, Petra Simon, Andrea Breitkreuz, et al.
European Journal of Haematology|July 12, 2018
<sup>90</sup> Y-ibritumomab-tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single-center experienceEva U Spukti, Lars Henning Schmidt, Arik Schulze, et al.
Oncoimmunology|July 30, 2013
HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patientsHans-Henning Schmidt, Yingzi Ge, Felix J Hartmann, et al.
Cancers|March 25, 2022
High Expression of NT5DC2 Is a Negative Prognostic Marker in Pulmonary AdenocarcinomaArik Bernard Schulze, Anna Kuntze, Lars Henning Schmidt, et al.
Plos Genetics|January 6, 2016
Prp4 Kinase Grants the License to Splice: Control of Weak Splice Sites during Spliceosome ActivationDaniela Eckert, Nicole Andrée, Aleh Razanau, et al.
Thoracic Cancer|November 25, 2019
Prognostic impact of CD34 and SMA in cancer-associated fibroblasts in stage I-III NSCLCArik Bernard Schulze, Lars Henning Schmidt, Birthe Heitkötter, et al.
Journal of Thoracic Disease|November 19, 2019
Blood clot removal by cryoextraction in critically ill patients with pulmonary hemorrhageLars Henning Schmidt, Arik Bernard Schulze, Dennis Goerlich, et al.
Translational Lung Cancer Research|May 17, 2023
High expression of transcription factor POU2F1 confers improved survival on smokers with lung adenocarcinoma: a retrospective study of two cohortsArik Bernard Schulze, Daniela Vanessa Wenge, Georg Evers, et al.
Pageof 8